Given this recurrent BRAF alteration in a tumor type with frequent MAP kinase pathway activation and low somatic mutation burden, together with a lack of other identifiable alterations in MAP kinase pathway genes in these four tumors, this very likely represents a novel hotspot BRAF mutation causing activation of the serine/threonine kinase domain in gangliogliomas. This evidence concerns the gene MARK2 and ganglioglioma.